Until now, research on the prevalence of LTBI in patients with rheumatic immune diseases has mainly focused on arthritis patients treated with tumor necrosis factor alpha (TNF-α) antagonists (9, 10), while research on the prevalence of LTBI in SLE patients has lacked multicenter, large-sample data for all countries. Here, TNF is linked to systemic lupus erythematosus.